Meridian Bioscience, Inc. (VIVO)

NASDAQ: VIVO · IEX Real-Time Price · USD
32.71
+0.16 (0.49%)
Aug 12, 2022 4:00 PM EDT - Market closed
0.49%
Market Cap 1.43B
Revenue (ttm) 343.55M
Net Income (ttm) 43.41M
Shares Out 43.75M
EPS (ttm) 0.99
PE Ratio 33.04
Forward PE 40.49
Dividend n/a
Ex-Dividend Date n/a
Volume 311,312
Open 32.56
Previous Close 32.55
Day's Range 32.55 - 32.92
52-Week Range 17.20 - 34.38
Beta 0.28
Analysts Sell
Price Target 34.68 (+6.0%)
Earnings Date Aug 5, 2022

About VIVO

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid im... [Read more...]

Industry Health Care Equipment & Supplies
CEO John Kenny
Employees 702
Stock Exchange NASDAQ
Ticker Symbol VIVO
Full Company Profile

Financial Performance

In 2021, VIVO's revenue was $317.90 million, an increase of 25.32% compared to the previous year's $253.67 million. Earnings were $71.41 million, an increase of 54.61%.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for VIVO stock is "Sell." The 12-month stock price forecast is 34.68, which is an increase of 6.02% from the latest price.

Price Target
$34.68
(6.02% upside)
Analyst Consensus: Sell
Stock Forecasts

News

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, ONEM, HNGR

NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of...

Other symbols: HNGRONEM

Meridian Bioscience (VIVO) Meets Q3 Earnings Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 0% and 1.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS

CINCINNATI , Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comp...

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

CINCINNATI , July 29, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received ...

MERIDIAN BIOSCIENCE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates A...

NEW ORLEANS , July 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Meridian Bioscience, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - July 8, 2022) - Rigrodsky Law, P.A. is investigating Meridian Bioscience, Inc. ("Meridian") (NASDAQ: VIVO) regarding possible breaches of fiduciary duties and oth...

MERIDIAN BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates A...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Meridian Bioscienc...

SHAREHOLDER ALERT: Weiss Law Investigates Meridian Bioscience, Inc.

NEW YORK , July 7, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Meridian Bioscience, Inc. ("Meridian" or t...

Shareholder Alert: Ademi LLP investigates whether Meridian Bioscience, Inc. has obtained a Fair Price in its transact...

MILWAUKEE , July 7, 2022 /PRNewswire/ -- Ademi LLP is investigating Meridian (NASDAQ: VIVO) for possible breaches of fiduciary duty and other violations of law in its transaction with the Consortium.  C...

Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement

VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The post Meridian Biosciences (VIVO) Stock Trending on $1.5...

VIVO Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Meridian Bioscience, Inc. Is Fair to Sharehol...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Meridian Bioscience, Inc. (NASDAQ: VIVO) to SD Biosensor, Inc. and SJL Partners LLC for $34...

Meridian Bioscience agrees to $1.5 billion buyout by SD Biosensor, SJL Partners

Meridian Bioscience Inc. VIVO, +7.02% announced an agreement Thursday to be acquired by a consortium of South Korea-based SD Biosensor Inc. 137310, +2.08% and private equity firm SJL Partners LLC in a c...

Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-...

Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partner...

Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter

CINCINNATI , July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials...

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

CINCINNATI , June 20, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new sam...

Meridian Bioscience (VIVO) Moves 5.7% Higher: Will This Strength Last?

Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Developm...

CINCINNATI , May 26, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that its inh...

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its particip...

Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of...

CINCINNATI , May 17, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the continue...

Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

Meridian Bioscience Inc (NASDAQ: VIVO) reported a 30% increase in Q2 sales to $111.2 million, the highest in the company's history, with both segments ahead of expectations, beating the consensus of $99...

Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 37.50% and 11.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

CINCINNATI , May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Co...

Meridian Bioscience (VIVO) is on the Move, Here's Why the Trend Could be Sustainable

Meridian Bioscience (VIVO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro...

Why Earnings Season Could Be Great for Meridian Bioscience (VIVO)

Meridian Bioscience (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.